[Myasthenia gravis].
Kawaguchi
Naoki
N
Department of Neurology, Chiba University Graduate School of Medicine.
Hattori
Takamichi
T
D000203:Activities of Daily Living; D001323:Autoantibodies; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D017410:Practice Guidelines as Topic; D011379:Prognosis; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D011950:Receptors, Cholinergic / Q000276:immunology; D011978:Receptors, Nicotinic / Q000276:immunology; D019837:Ryanodine Receptor Calcium Release Channel / Q000276:immunology; D016060:Sorption Detoxification; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D013934:Thymectomy
D001323:Autoantibodies; D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D019837:Ryanodine Receptor Calcium Release Channel; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases